|Human fibroblast (Photo credit: glyn_nelson)|
‘Pseudo’ poly (aminoacids) such as L-Tyrosine polyurethanes (LTUs) have been synthesized by the structural modiﬁcation of poly (aminoacids) by incorporation of non-peptide bonds into the polymer’s backbone. These bioplolymers have superior mechanical properties (particularly their excellent elasticity) without cytotoxic degradation products. They augment fibroblastic adhesion and proliferation that is even tunable to certain extend by subtle changes in the polymer structure.
I dare go to the extent of predicting it as a next generation hair loss treatment because of its ideal rheological properties as a scaffold for blood-vessel generation as I hypothesised before.
GlaxoSmithKline has a unique topical steroid molecule called GW870086 in the pipeline that could change the way we treat inflammatory skin disorders. A modification of the 17α position of the steroid nucleus resulted in a molecule that retained the effect on anti-inflammatory targets while having minimal impact on the expression of other known target genes responsible for the side effects. The properties of GW870086 were compared to fluticasone propionate (FP) using a range of model systems, including extensive gene expression profiling. Murine models of irritant-induced contact dermatitis showed promising results. If the same efficacy and safety profiles can be demonstrated on humans as well, it may fulfill our long quest for a safe topical steroid.
Special thanks to Dr Yun of University of Akron and Dr Uings of GSK and their respective teams for the details.